Neuromod launches Ótologie to provide specialist healthcare service for tinnitus patients, helping them avoid waiting lists – PR Newswire UK
DUBLIN, Jan. 13, 2022 /PRNewswire/ — Medical device company, Neuromod Devices Ltd, has launched Ótologie, a specialist telehealth service for tinnitus. This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
– £750 million annual cost to NHS of treating tinnitus
– Ótologie allows patients to start treatment within day…….
DUBLIN, Jan. 13, 2022 /PRNewswire/ — Medical device company, Neuromod Devices Ltd, has launched Ótologie, a specialist telehealth service for tinnitus. This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
– £750 million annual cost to NHS of treating tinnitus
– Ótologie allows patients to start treatment within days
The establishment of Ótologie comes as 45% of patients waiting to start treatment with a public Ear Nose and Throat (ENT) consultant faced a waiting time of more than 18 weeks, according to NHS England [i]. It also follows research from Neuromod which found that more than three quarters of people living from tinnitus in the UK have never received any treatment for their condition.
The research, which polled 251 people with tinnitus across the UK, found that 76.1% of respondents have never used any form of tinnitus treatment. It also revealed that 67.7% of those polled don’t feel adequately informed about tinnitus.
Neuromod’s establishment of Ótologie follows a successful pilot by the company to provide a telehealth service for tinnitus care to UK patients in 2021. Due to the success of the pilot, which allowed patients to avoid waiting lists and progress to treatment within days of contacting the service, Neuromod has launched Ótologie to provide quick access to tinnitus care from qualified healthcare professionals who can prescribe a range of proven treatments including Lenire, Cognitive Behavioural Therapy (CBT), and hearing aids.
Tinnitus, commonly known as “ringing in the ears” affects between 10 and 15% of the global population and the British Tinnitus Association estimates that more than seven million people suffer from this condition in the UK alone [ii].
In accordance with National Institute for Health and Care Excellence (NICE) guidelines, many tinnitus patients are referred to public ENT waiting lists and studies have estimated that treating tinnitus costs the NHS £750 million annually [iii]. The estimated cost to society caused by tinnitus reaches approximately £2.7 billion [iii] demonstrating the need for private care options specifically for tinnitus, such as Ótologie, to increase the number of people tinnitus accessing treatment by avoiding waiting lists.
Speaking on the launch of Ótologie, Dr Ross O’Neill, CEO of Neuromod Devices said: “Studies have shown that treating tinnitus costs the NHS approximately £750 million every year and it also estimates that the cost to society reaches around £2.7 billion [iii]. This, combined with lengthy waiting lists, shows the significant healthcare challenge treating people with tinnitus poses.”
“Ó…….
